<?xml version="1.0" encoding="UTF-8"?>
<ref id="B42">
 <label>42.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Van Roy</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Ververken</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Beirnaert</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Hoefman</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Kolkman</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Vierboom</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis.</article-title>
  <source>
   <italic>Arthritis Res Ther.</italic>
  </source> (
  <year>2015</year>) 
  <volume>17</volume>:
  <issue>135</issue>. 
  <pub-id pub-id-type="doi">10.1186/s13075-015-0651-0</pub-id>
  <?supplied-pmid 25994180?>
  <pub-id pub-id-type="pmid">25994180</pub-id>
 </mixed-citation>
</ref>
